Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-29
2002-01-15
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255030
Reexamination Certificate
active
06339100
ABSTRACT:
The invention described herein was made with Government support under grant numbers RO1 AR43356 and P30 AR44535 from the National Institutes of Health. Accordingly, the United States Government has certain rights in this invention.
Throughout this application, various publications are referenced within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citations for these references may be found immediately preceding the claims.
BACKGROUND OF THE INVENTION
Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT proto-oncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis of neoplastic mast cells. To develop potential therapies for mastocytosis we used indolinones, small molecules which inhibit tyrosine kinases. An indolinone derivative with structure VI (see below) or structure VII inhibited wild-type KIT, but variably inhibited constitutively activated KIT mutants. The compounds with structure VI or structure VII were effective against KIT with juxtamembrane activating mutations. Furthermore, the compounds with structure VI or structure VII killed neoplastic mast cells expressing a juxtamembrane-mutated KIT, whereas the compound with structure VII killed neoplastic mast cells expressing KIT bearing a kinase domain mutation. These data show a direct correlation between inhibition of constitutively activated KIT and the death of neoplastic mast cells, and point to specific tyrosine kinase inhibitors as a novel therapy aimed directly at a cause of mastocytosis.
SUMMARY OF THE INVENTION
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject, wherein
R
1
is H or alkyl; R
2
is O or S; R
3
is hydrogen;
R
4
, R
5
, R
6
, and R
7
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
R
8
, R
9
, and R
10
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
n is 0-3; x is Br, Cl, F or I; each of R and R′ is independently H, alkyl or aryl.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject, wherein R
1
is H or alkyl; R
2
is O or S; R
3
is hydrogen;
R
4
, R
5
, R
6
, and R
7
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
R
8
, R
9
, R
10
and R
11
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
Ra and Rb are each independently hydrogen, alkyl and C(O)R, or NRaRb taken together may be a heterocyclic ring of 3 to 8 atoms optionally substituted at one or more positions with hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
n is 0-3; x is Br, Cl, F or I; and each of R and R′ is independently H, alkyl or aryl.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject, wherein R
1
is H or alkyl; R
2
is O or S; R
3
is hydrogen;
R
4
, R
5
, R
6
, and R
7
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
A is a five membered heteroaryl ring thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, or tetrazole, optionally substituted at one or more positions with alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO2, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
n is 0-3; x is Br, Cl, F or I; and each of R and R′ is independently H, alkyl or aryl.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject, wherein R
1
is H or alkyl; R
2
is O or S; R
3
is hydrogen;
R
4
, R
5
, R
6
, and R
7
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
R
8
, R
9
and R
10
and R
11
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
n is 0-3; x is Br, Cl, F or I; each of R and R′ is independetly H, alkyl or aryl.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject, wherein RI is HI or alkyl; R
2
is O or S; R
3
is hydrogen;
R
4
, R
5
, R
6
, and R
7
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR ′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH2)
n
CO2R, or CONRR′;
R
8
, R
9
, R
10
and R
11
are each independently hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO
2
NRR′, SO
3
R, SR, NO
2
, NRR′, OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH
2
)
n
CO2R, or CONRR′;
n is 0-3; Z is Br, Cl, F, I, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, or tert-butyl; and each of R and R′ is independently H, alkyl or aryl.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject.
This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceuti
Cooper & Dunham LLP
Criares Theodore J.
Kim Jennifer
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Methods for inhibiting mastocytosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting mastocytosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting mastocytosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2852794